Prestige Consumer Healthcare - PBH Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.

6 brokerages have issued 1-year price targets for Prestige Consumer Healthcare's shares. Their PBH share price forecasts range from $70.00 to $104.00. On average, they expect the company's stock price to reach $77.40 in the next twelve months. This suggests a possible upside of 25.9% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.

Prestige Consumer Healthcare's stock was trading at $62.60 at the beginning of 2023. Since then, PBH shares have decreased by 1.8% and is now trading at $61.49.
View the best growth stocks for 2023 here.

Prestige Consumer Healthcare saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,100,000 shares, an increase of 20.2% from the February 28th total of 914,900 shares. Based on an average daily volume of 276,400 shares, the short-interest ratio is presently 4.0 days. Currently, 2.2% of the company's stock are short sold.
View Prestige Consumer Healthcare's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PBH earnings forecast.

Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings data on Thursday, February, 2nd. The company reported $1.04 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. The business had revenue of $275.50 million for the quarter, compared to analysts' expectations of $273.84 million. Prestige Consumer Healthcare had a net margin of 18.97% and a trailing twelve-month return on equity of 12.65%. The business's revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.99 EPS.

ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), SPDR S&P Pharmaceuticals ETF (XPH), Global X Health & Wellness ETF (BFIT), iShares U.S. Pharmaceuticals ETF (IHE) and ETC 6 Meridian Small Cap Equity ETF (SIXS).

Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided EPS guidance of $4.18-$4.18 for the period, compared to the consensus earnings per share estimate of $4.20. The company issued revenue guidance of $1.12 billion-$1.12 billion, compared to the consensus revenue estimate of $1.12 billion.

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (7.40%), Macquarie Group Ltd. (3.97%), Allspring Global Investments Holdings LLC (2.14%), Nordea Investment Management AB (2.07%), Geode Capital Management LLC (1.84%) and LSV Asset Management (1.74%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBH stock can currently be purchased for approximately $61.49.

Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $3.06 billion and generates $1.09 billion in revenue each year. The company earns $205.38 million in net income (profit) each year or $4.17 on an earnings per share basis.

The company employs 505 workers across the globe.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.